Blenrep (belantamab mafodotin-blmf)

article

Antibody-drug conjugates: challenges, solutions and future potential

20 April 2021 | By Dave Elder (David P Elder Constultancy), Stacey Treichler (Catalent)

The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.

article

EMA’s transformative treatments of 2020

24 February 2021 | By Hannah Balfour (European Pharmaceutical Review)

In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.

news

Blenrep granted CMA for relapsed or refractory multiple myeloma

28 August 2020 | By Hannah Balfour (European Pharmaceutical Review)

The European Commission granted the conditional marketing authorisation (CMA) based on data from a trial in which Blenrep achieved an overall response rate of 32 percent.